ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib-MedSci.cn

ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib

De Langen, J; Cho, BC; Piotrowska, Z; Le, X; Goldberg, SB; Goldman, JW; Okamoto, I; Hewson, N; Maidment, J; Tang, KH; Veney, N; Cosaert, J; Lau, J; Dressman, M; Ambrose, H; Riess, JW; Yu, HA

ANNALS OF ONCOLOGY, 2022; 33 (7): S1091

科室
- - 订阅+
  - 更多科室
工具
服务